J. Clin. Invest. https://doi.org/10.1172/JCI91512 (2018)
The stability of vaccines can be an important consideration for both their in vivo efficacy and their use in the field, which often necessitates a cold-chain deployment. In The Journal of Clinical Investigation, Sewell and colleagues use a synthetic-biology approach to generate a more stable peptide vaccine against influenza A virus. Nature tends to use l-amino acids; therefore, d-amino acid–based peptides can be more resistant to enzymatic digestion. Using a combinatorial peptide library, the authors generate a vastly more stable d-amino acid nonamer peptide that binds HLA-A2, albeit somewhat weakly, yet is able to robustly stimulate a protective influenza A virus–specific response in humanized mice. The d-amino acid peptide is also stable in a simulated gastric environment and is protective in vivo after oral vaccination.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fehervari, Z. Synthetic benefits. Nat Immunol 19, 510 (2018). https://doi.org/10.1038/s41590-018-0100-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-018-0100-8